Revvity is showing a real earnings recovery, led by strong Diagnostics growth and improving Life Sciences momentum. But the stock already reflects much of that progress, with leverage and valuation keeping the rating at Hold.
Revvity Inc. (RVTY) is a quality life sciences and diagnostics business moving through an uneven but important earnings recovery. The investment case rests on three facts: Diagnostics delivered 11.0% organic growth in Q2 2026, high-content screening demand is running ahead of near-term production capacity, and management raised full-year 2026 guidance to $2.83B to $2.86B of pro forma revenue and $5.30 to $5.40 of adjusted EPS.
The counterweight is valuation and leverage. RVTY trades at 70.3x trailing earnings and 24.9x forward earnings, while total debt stood at $3.2B against $919.9M of cash at fiscal year-end 2025. The reference share price of $129.71 also sits above the $126.12 analyst consensus target. That combination supports a Hold for a moderate-risk investor, rather than a purchase based solely on the AI narrative.
The medium-term setup improves when Diagnostics resilience, software expansion, high-content screening, and debt reduction are considered together. The key risk is that current earnings strength includes a $16M tariff refund and favorable tax timing, so the 2026 profit step-up is not entirely operational.
Revvity is a Waltham, Massachusetts-based health sciences company with approximately 11,000 employees. Founded in 1937 and formerly known as PerkinElmer, the company changed its name to Revvity in April 2023. Its products include instruments, reagents, assays, software, subscriptions, services, and diagnostics.
The company operates through two reportable segments: Life Sciences and Diagnostics. Life Sciences serves pharmaceutical and biotechnology companies, academic and research institutions, laboratories, and government customers. Diagnostics serves public health authorities, private healthcare organizations, doctors, government agencies, and clinical laboratories.
Revvity's portfolio covers reproductive health, newborn screening, immunodiagnostics, genetic testing, high-content screening, genomics, proteomics, drug discovery, laboratory informatics, and scientific software. That breadth gives the company exposure to both recurring clinical workflows and more cyclical research spending.
Diagnostics is currently the stronger operating engine. Q2 2026 Diagnostics revenue was $371M, up 12.0% on a reported basis and 11.0% organically. Adjusted operating income reached $113M, up from $89M a year earlier, while adjusted operating margin expanded to 30.4% from 25.2%.
Reproductive health grew in the double digits, supported by newborn screening and the Genomics England sequencing contract. Immunodiagnostics also grew at a high-single-digit organic rate outside China. This performance gives Diagnostics a more defensive profile than instrument-heavy research businesses, although reimbursement, public-health budgets, and regulatory requirements remain important variables.
Life Sciences generated Q2 revenue of $359M, down 2.0% on a reported basis and 3.0% organically. Adjusted operating income was $112M, compared with $115M a year earlier, and adjusted operating margin was 31.1%. The headline decline was driven by a roughly 20.0% drop in Signals software revenue against a difficult comparison and contract timing.
The underlying Life Sciences picture is better than the segment headline. Life Sciences Solutions grew at a low-single-digit organic rate, with both reagents and instrumentation producing positive growth. Management raised its full-year platforms outlook from low-single-digit growth to mid-single-digit growth as instrument orders accelerated.
Revvity also entered a definitive agreement to divest its China immunodiagnostics business, which represented approximately 6.0% of fiscal 2025 revenue. Management expects the transaction to close by the end of 2027 and now presents its organic growth and adjusted earnings outlook on a pro forma basis excluding that business.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The Opera Phenix OptIQ is Revvity's flagship high-content screening instrument and a central product in the Life Sciences recovery story. Management described demand as robust, with double-digit year-over-year growth despite a difficult comparison.
The instrument sells for more than $1M and is complex to manufacture, which limits rapid production increases. Management reported that order velocity outpaced near-term production capacity during Q2 and that some deliveries moved into Q3. That backlog represents a near-term revenue conversion opportunity, although execution depends on manufacturing throughput and customer installation schedules.
OptIQ also creates a consumables pathway. Customers use high-content screening reagents to generate and validate biological data, so additional instrument placements support later reagent demand. This instrument-plus-reagent model is strategically stronger than a one-time equipment sale because the installed base can expand recurring laboratory consumption.
The product fits the emerging Lab-in-the-Loop workflow described by management. AI systems generate hypotheses, while OptIQ instruments and related reagents provide the physical experiments and biological data required to validate those hypotheses.
Revvity's strongest competitive argument is workflow integration. The company combines instruments, reagents, software, data management, and scientific services across discovery and diagnostic processes. Customers that validate procedures, train staff, and organize proprietary data around a workflow face friction when changing platforms.
Signals software is the digital layer of this strategy. Signals AI embeds large language model capabilities into the platform, while the Anthropic connector lets customers use proprietary scientific data with Claude and Claude Science. Management described these products as complementary additions that support retention and consumption-based revenue.
The product pipeline also includes BioDesign for large-molecule workflows, Synthetica for AI models as a service, and LabGistics for workflow coordination from discovery through manufacturing. Signals for Startups expands the addressable customer base by giving smaller biotechnology companies a predefined software entry point.
The acquisition of ACD/Labs adds another software capability and contributed approximately 75 basis points to 2026 revenue growth. Early integration progress and product interoperability give Revvity a concrete route to increase software attachment, rather than relying on AI as a purely promotional label.
The Q2 operating data show both strong demand and capacity pressure. The Opera Phenix OptIQ backlog reached its strongest position in three to four years, while larger screening-related reagent orders also moved into Q3. Management added resources during the quarter to support demand.
Revvity is also executing footprint consolidation, supply-chain optimization, and cost initiatives. Investor materials describe a program targeting approximately 20.0% annual cost reductions and a 10.0% footprint reduction by 2027, affecting more than 30 locations. The benefit profile is attractive, but implementation requires careful coordination across manufacturing, distribution, and customer service.
Tariff refunds provided $16M of Q2 support, and management said roughly half of the adjusted EPS upside came from those refunds. The company is reinvesting part of the benefit in strategic initiatives, supply chain, and employees. That decision protects capacity for the demand recovery but reduces the immediate margin benefit.
Geographic performance was mixed in Q2. Europe delivered double-digit growth, Asia-Pacific grew at a low-single-digit rate, and the Americas declined at a low-single-digit rate because of software comparisons and latent tuberculosis pressures. This regional spread reinforces the value of a diversified customer base while exposing the company to foreign exchange, trade policy, and local funding conditions.
The global life science tools market was estimated at $153.81B in 2025 and $164.47B in 2026, with a projected 6.9% compound annual growth rate from 2026 through 2031. The United States market was estimated at $54.65B in 2026, with a projected 5.1% growth rate through 2031.
Growth is concentrated in areas connected to Revvity's portfolio. Next-generation sequencing was projected to grow at a 16.9% rate, proteomics at 13.1%, and life science analytics at 11.5%. Gartner also projected 2025 healthcare and life sciences enterprise technology spending growth of 7.3%, with software spending growth of 9.8%.
The market is shifting from standalone equipment toward integrated platforms that combine hardware, reagents, data, and services. Revvity's OptIQ, Signals, high-content screening reagents, and diagnostic workflows fit this direction. Its 2026 guidance of 4.0% to 5.0% organic growth is below the fastest-growing market niches, but Diagnostics growth and Life Sciences backlog provide evidence of improving demand.
The market also carries clear cyclical features. Instruments remain a large portion of industry revenue, and customers include biotechnology companies and academic institutions that adjust capital spending when funding conditions tighten. Services and recurring consumables have stronger structural characteristics than one-time equipment purchases, which makes Revvity's mix important to the investment case.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Revvity serves four broad customer groups: pharmaceutical and biotechnology companies, academic and government research organizations, clinical and diagnostic laboratories, and public health agencies. Its product range allows the company to sell into both research workflows and regulated clinical testing.
Pharma and biotech customers remained mixed in Q2. Sales to the group declined at a mid-single-digit rate because of the Signals comparison, while sales excluding software grew at a low-single-digit rate. Management also reported the third consecutive quarter of improving conditions across these end markets and higher instrument backlog entering the second half.
Academic and government sales declined at a low-single-digit rate in Q2, again reflecting software-related comparisons. Diagnostics customers produced the strongest results, with reproductive health benefiting from newborn screening and the Genomics England contract, while immunodiagnostics outside China grew at a high-single-digit organic rate.
The customer relationship is reinforced by workflow validation, recurring reagents, software data storage, instrument service, training, and extended warranties. Those offerings create several revenue touchpoints after an initial platform purchase and strengthen retention when customers build processes around Revvity's tools.
Revvity competes with Thermo Fisher Scientific, Danaher, Agilent Technologies, Bio-Rad Laboratories, Merck KGaA and its MilliporeSigma business, and Luminex across life science tools and diagnostics. It also faces specialized competition from Bio-Techne, Bruker, Waters, Sartorius, Quanterix, Seer, SomaLogic, and other proteomics and analytical technology providers.
Thermo Fisher and Danaher bring broader scale and distribution. Agilent and Waters are strong in analytical workflows, Bio-Rad competes in research reagents and diagnostics, and Bio-Techne is closer to Revvity in research reagents and immunoassay tools. Revvity's advantage is a focused combination of Diagnostics, high-content screening, reagents, and scientific software.
Competition is strongest where products are interchangeable and customers purchase primarily on instrument price. Revvity's position improves when the sale includes validated assays, recurring consumables, data management, workflow software, and service. The Q2 backlog for OptIQ and management's emphasis on Lab-in-the-Loop workflows provide concrete evidence of differentiation in a high-value niche.
The strategic divestiture of China immunodiagnostics also narrows the portfolio toward businesses where management sees more durable returns. That improves focus, although it removes a revenue stream that contributed to the historical Diagnostics base.
Revvity's macro exposure runs through biotechnology funding, pharmaceutical research budgets, academic grants, diagnostic testing volumes, tariffs, foreign exchange, and China policy. Q2 results captured this split: Europe grew at a double-digit rate, Asia-Pacific grew at a low-single-digit rate, and the Americas declined at a low-single-digit rate.
Tariffs were a direct earnings factor in Q2. Revvity received $16M of tariff-related refunds, and management said additional refunds would be immaterial to overall results. The refund lifted current-period earnings but does not represent a recurring operating improvement.
China remains the clearest geopolitical issue. The company agreed to divest its China immunodiagnostics business, representing approximately 6.0% of fiscal 2025 revenue, and expects closing by the end of 2027. The transaction reduces direct exposure to a structurally difficult market while adding separation and regulatory execution requirements.
Export controls and supply-chain fragility are broader industry risks. Life science tools companies depend on specialized components, trained personnel, and compliant distribution networks. Revvity's investments in supply chain and employees address those pressures, but they also explain why management is reinvesting part of the tariff benefit instead of allowing the entire amount to flow through margins.
Total debt of $3.2B versus $919.9M of cash leaves Revvity with meaningful leverage, even as the company continues to generate solid operating cash flow.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 Diagnostics revenue rose 11.0% organically to $371M and adjusted operating margin expanded to 30.4%, but Life Sciences revenue fell 3.0% organically on a tough software comparison.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 pro forma revenue guidance to $2.83B-$2.86B and adjusted EPS to $5.30-$5.40, helped by stronger instrument orders and a better platform outlook.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revvity trades at 70.3x trailing earnings and 24.9x forward earnings, a premium that leaves little room for execution missteps while the share price sits above $126.12.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $129.71, Revvity is trading above the $126.12 consensus target, which is why the report stops short of a Buy despite improving fundamentals.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revvity has moved from restructuring toward execution. Diagnostics is producing durable growth, OptIQ demand is creating a meaningful instrument and reagent backlog, Signals is adding AI functionality, and management is using strong cash generation to reduce leverage while funding capacity.
The investment case is not risk-free. Fiscal 2025 revenue growth was modest, the five-year earnings record includes a loss in 2023, debt remains material, and Q2 adjusted earnings benefited from $16M of tariff refunds and favorable tax timing. Those facts keep the valuation discipline intact.
For a medium-term investor, RVTY is a Hold with a constructive operating outlook and limited valuation margin at $129.71. A move toward $119.00 would improve the entry profile, while sustained Diagnostics growth, software acceleration, and net leverage near 2.0x would strengthen the case for a higher long-term valuation.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Revvity, Inc. (RVTY) rises sharply after conference commentary reinforced its better-than-expected second quarter and raised 2026 outlook. Strong volume, improving diagnostics momentum, and a breakout above its 52-week high are fueling the move, though valuation remains elevated and the stock now trades above the analyst consensus target.
Revvity is showing a credible medium-term recovery, powered by software, reproductive health, and high-content imaging. But the stock already prices in much of the improvement, leaving limited upside at current levels.
Revvity, Inc. (RVTY) rises after a clean Q1 earnings beat, but the real story is in the details: stronger-than-expected margins, steady organic growth, and a guidance reset tied to a strategic China exit rather than core business weakness. Here’s what the numbers and outlook really mean.